Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

Development hurdles & treatment challenges Unmet need: Remaining opportunity in MS Reversing neuronal damage Area of highest medical need… Importance Preventing disease progression Improved therapy for chornic-progressive multiple sclerosis More-convenient drug delivery Improved diagnostic criteria Improved animal models Level of attainment Source: Decision Resources Inc. Low attainment/ high opportunity Medium attainment/ medium opportunity High attainment/ low opportunity 70
<strong>Roche</strong>’s emerging multiple sclerosis portfolio New approaches to MS therapy – multiple opportunities MabThera (anti CD-20) • Phase II (HERMES) in RRMS met primary endpoints • Data presented at AAN ‘07 • Phase II/III in PPMS (OLYMPUS) – results in H1 2008 Ocrelizumab (hum. anti CD-20) • Phase II / III in RRMS in preparation R1295 • Orally active • Phase II in preparation R3477 (S1P1 receptor agonist) • Phase I - joint development with Actelion • Inhibits migration and recirculation of lymphocytes from lymph nodes • Orally active • In development for multiple autoimmune disorders, including MS 2 phase III projects (ongoing, in preparation) 2 phase I projects 71
Page 2 and 3:
Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5:
Introduction Dr. Karl Mahler Head o
Page 6 and 7:
Roche’s key therapeutic areas Cur
Page 8 and 9:
RA: A very concentrated market 6.00
Page 10 and 11:
Increased penetration of biologics
Page 12 and 13:
Actemra: The OPTION trial results P
Page 14 and 15:
Elevated IL-6 plays central role in
Page 16 and 17:
The OPTION study TOcilizumab Pivota
Page 18 and 19:
Demographics Intent-to-treat popula
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 52 and 53: Rates of serious infection Similar
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57: Overview of autoimmune disorders IN
Page 58 and 59: Not all patients respond to current
Page 60 and 61: Major players are active in this ar
Page 62 and 63: Actemra Potential to become a signi
Page 64 and 65: Ocrelizumab in autoimmune diseases
Page 66 and 67: Multiple sclerosis An emerging ther
Page 68 and 69: Prevalence of MS in Europe ~260,000
Page 72 and 73: Roche in autoimmune disorders Roche
show all

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

Create successful ePaper yourself

Delete template?

Save as template?